Sara M. Tolaney, MD, MPH, talks about the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients, means…
Browsing: Breast
Breast Cancer
Sara M. Tolaney, MD, MPH, the fulvestrant + ribociclib arm of the MONALEESA-3 study
Sara M. Tolaney, MD, MPH, talks about whether CDK4/6 inhibitors can be used interchangeably at Annual Meeting 2018.
Sara M. Tolaney, MD, MPH shares the MONARCH 2 study in pre and peri-menopausal ER+, HER2- breast cancer patients
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares Use PARP-Inhibitors Early in Therapy for Metastatic Breast…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco explains Talazoparib is Effective in Neoadjuvant Setting | Combine…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trastuzumab-DKST has Regulatory Approval in US |…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trial for PARP-Inhibitor for Germ-Line in BRCA1…
Hannah Linden, MD, University of Washington shares Publish New Abstract Data Next Year | Complete Accrual of Estrogen Receptor Imaging…
Hannah Linden, MD, University of Washington shares The Point of Estrogen Receptor Imaging? | If Receptor Functions & Need Endocrine…
Hannah Linden, MD, University of Washington shares ER Imaging Not Ready for Commercial Use | Working Hard With Tracer Manufacturers…
Hannah Linden, MD, University of Washington shares Estrogen Receptor Imaging | Lobular Tumors Detectable by FES PET
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Therapies for Metastatic Breast Cancer | Clinical Trial Development is Key to…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Triple Negative Breast Cancer Immunotherapies | Pemborlizumab works in NeoAdjuvant Setting at…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Vaccine Immunotherapy with Cytoxan & Interferon | Eventually add Ipilimumab or Pembrolizumab…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Metastatic Breast Cancer Does Well with Bria-IMT Side-Effect Profile Not as Severe…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Phase 1 & 2 Trial of Bria-IMT | Immunotherapy with Cytoxan &…
Jennifer K. Litton, MD, explains The Number of Agents Has Exploded Impactful Studies Happen with Federal Funding at Annual Meeting…
Jennifer K. Litton, MD, MD Anderson Cancer Center, talks about TAILORx Trial is Confirmatory Group of Patients Avoiding Chemo-Therapy at…
Jennifer K. Litton, MD, MD Anderson Cancer Center, talks about Warranting Larger Ongoing Confirmatory Study Possibility of Avoiding Chemo-Therapy in…
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Biopsies Pre- & Post-PARP inhibitors Combination Studies for Response Beyond BRCA…
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Warrants Larger Ongoing Confirmatory Study Possibility of Avoiding Chemo-Therapy in BRCA…
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Feasibility Study with 2 Months of Talazoparib Tumor Volume Decrease of…
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Talazoparib – Active in Metastatic Breast Cancer Pathologic Complete Response Rate…
Chuck Wiseman, MD, BriaCell Therapeutics, talks about Rollover Protocol Approval Bria-IMT in combination with a checkpoint inhibitor at Annual Meeting…
Chuck Wiseman, MD BriaCell Therapeutics, discusses Cell Preparation Bria-IMT Confirms that similar vaccine therapies can regress advances at Annual Meeting…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains KLLN & SEC23B Novel Predisposition Genes Prediction tools for…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains SEC23B is Altered For Rare Blood Disorder Type II…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains SEC23B is Very Rarely Studied in Cancer Enters the…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains KLLN is Right Next to PTEN Gene Might play…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains 3D Modeling of PTEN Tumor Suppressor at AACR 2018.